Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18842878 | 0.89 | TSHR (0.35) | TSHR | |
| SCHEMBL20970852 | 0.82 | HTR1A (0.35) | OPRM1OPRD1OPRK1OPRL1KDM2B | |
| SCHEMBL18559577 | 0.82 | TSHR (0.37) | TSHR | |
| SCHEMBL22414444 | 0.81 | USP2 (0.31) | TSHR | |
| SCHEMBL20153178 | 0.81 | CYP3A4 (0.48) | TSHRHSD17B10 | |
| SCHEMBL24688458 | 0.79 | OPRM1 (0.32) | OPRM1OPRD1OPRK1OPRL1KDM2B | |
| SCHEMBL21216976 | 0.79 | TSHR (0.37) | TSHROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL21364233 | 0.78 | TSHR (0.46) | TSHR | |
| SCHEMBL19928539 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL21163920 | 0.78 | OPRM1 (0.35) | TSHROPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-10329280-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | TSHR 857/4885OPRM1 3571/4885OPRD1 3394/4885 |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | TSHR 1461/4885OPRM1 2992/4885OPRD1 2355/4885 |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | TSHR 857/4885OPRM1 3571/4885OPRD1 3394/4885 |
| US-10329280-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | TSHR 857/4885OPRM1 3571/4885OPRD1 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.